Abstract： Objective To explore the therapeutic effect of alirocumab combined with atorvastatin in the treatment of ST segment elevation myocardial infarction and its impact on blood lipids and cardiac function in patients.Methods 70 patients with ST segment elevation myocardial infarction admitted to The Second People's Hospital of Jingdezhen from January 2021 to November 2022 were selected as the study subjects.They were randomly divided into a control group and an observation group using random number table method,with 35 patients in each group.The control group was treated with atorvastatin,while the observation group were treated with alirocumab on basis of the control group.Compare the clinical efficacy,blood lipid levels,and cardiac function indicators between the two groups of patients.Results The total effective rate of clinical treatment in the observation group was 88.57%,which was higher than 62.86%in the control group,with a statistically significant difference(P＜0.05).The low density lipoprotein cholesterol(1.97±0.35)mmol/L,triglyceride(1.30±0.52)mmol/L,left ventricular end systolic diameter(38.09±3.97)mm,and left ventricular end diastolic diameter(47.31±9.28)mm in the observation group were lower than those in the control group(3.11±0.69)mmol/L,(1.58±0.63)mmol/L,(41.71±4.21)mm,and(51.93±9.84)mm,The left ventricular ejection fraction of the observation group(62.01±6.35)%was higher than that of the control group(50.39±5.68)%,with a statistically significant difference(P＜0.05).Conclusion The combination of alirocumab and atorvastatin has a significant therapeutic effect on patients with ST segment elevation myocardial infarction,which can significantly improve the levels of blood lipid metabolism and cardiac function in the body of ST segment elevation myocardial infarction patients.